Biomarkers for Oncology
JH · Effective Oct 1, 2015
115 active Medicare policies list C91.00, and 8 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
Showing 100 of 115
JH · Effective Oct 1, 2015
JL · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
8 policies from 3 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of C91.00 |
|---|---|---|
| Donor Lymphocyte Infusion | Sep 13, 2023 | Covered |
| Hematopoietic Cell Transplantation for Selected Leukemias | Mar 5, 2024 | Covered |
| Non-myeloablative Hematopoietic Cell Transplantation (Mini-Allograft / Reduced Intensity Conditioning Transplant) | Feb 20, 2024 | Covered |
| Palivizumab (Synagis) | Feb 15, 2024 | Covered |
| Plerixafor | Jan 9, 2024 | Covered |
| Tumor Markers | Mar 5, 2024 | Covered |
J6 · Effective Jul 15, 2026
JK · Effective Jul 15, 2026
JJ · Effective Jul 24, 2022
JM · Effective Jul 24, 2022
J15 · Effective Oct 1, 2015
J15 · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
J15 · Effective Nov 1, 2020
JE · Effective Dec 6, 2020
JF · Effective Dec 6, 2020
JJ · Effective Oct 25, 2020
JM · Effective Oct 25, 2020
J5 · Effective Oct 25, 2020
J8 · Effective Oct 25, 2020
JE · Effective Aug 8, 2022
JF · Effective Aug 8, 2022
JJ · Effective Jul 3, 2022
JM · Effective Jul 3, 2022
J5 · Effective Jul 3, 2022
J8 · Effective Jul 3, 2022
J15 · Effective Dec 26, 2021
JE · Effective Jan 2, 2022
JF · Effective Jan 2, 2022
JJ · Effective Dec 26, 2021
JM · Effective Dec 26, 2021
J5 · Effective Dec 26, 2021
J8 · Effective Dec 26, 2021
J5 · Effective Feb 16, 2017
J8 · Effective Feb 16, 2017
J15 · Effective Aug 17, 2025
JE · Effective Aug 17, 2025
JF · Effective Aug 17, 2025
JJ · Effective Aug 17, 2025
JM · Effective Aug 17, 2025
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
JE · Effective Oct 8, 2018
JF · Effective Oct 8, 2018
J6 · Effective Nov 1, 2022
JK · Effective Nov 1, 2022
J9 · Effective Oct 1, 2015
J6 · Effective May 1, 2017
JK · Effective May 1, 2017
J6 · Effective Jul 13, 2025
JK · Effective Jul 13, 2025
J9 · Effective Dec 12, 2021
JH · Effective Dec 12, 2021
JL · Effective Dec 12, 2021
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
JJ · Effective Jun 12, 2017
JM · Effective Jun 12, 2017
JL · Effective Apr 24, 2025
National · Effective Oct 1, 2025
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
National · Effective Jul 15, 2026
National · Effective Sep 27, 2026
National · Effective Mar 5, 2026
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
J5 · Effective Aug 27, 2026
National · Effective Sep 24, 2026
National · Effective Sep 24, 2026
National · Effective Sep 24, 2026
J5 · Effective Oct 1, 2024
National · Effective Jan 22, 2026
National · Effective Oct 1, 2024
National · Effective Oct 1, 2024
National · Effective Aug 6, 2026
National · Effective Aug 13, 2026
J5 · Effective Aug 6, 2026
National · Effective Apr 24, 2025
National · Effective Feb 5, 2026
| Policy | Effective | Status of C91.00 |
|---|---|---|
| Concert Genetic Testing Oncology: Hematologic Malignancy | Not recorded | Referenced |
| Policy | Effective | Status of C91.00 |
|---|---|---|
| Donor Lymphocyte Infusion for Hematologic Malignancies after Allogeneic Hematopoietic Progenitor Cell Transplantation | Jul 1, 2026 | Covered |